Francisco Toledo, MD
Gastroenterology · Philadelphia, PANPI 1659359958
Payments from drug & device makers
Across 15 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$81
- Daiichi Sankyo Inc.$69
- Dova Pharmaceuticals$24
- Sanofi$20
- Rigel Pharmaceuticals, Inc.$19
- Incyte Corporation$19
- plus $57 from 4 others
What the payments were for
- Food & beverage$288100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 4 | $81 |
| Daiichi Sankyo Inc. | 3 | $69 |
| Dova Pharmaceuticals | 1 | $24 |
| Sanofi | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| Incyte Corporation | 1 | $19 |
| Foundation Medicine, Inc. | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Taiho Oncology, Inc. | 1 | $13 |
How this compares
$288 in reported general payments places this provider in the 15th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 33 | $6,563 |
| Mesalamine | 13 | $3,277 |
| Balsalazide Disodium | 12 | $1,146 |
| Omeprazole | 61 | $572 |
| Pantoprazole Sodium | 44 | $437 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 25 | $401 |
| Famotidine | 49 | $377 |
| Prochlorperazine Maleate | 24 | $370 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 19 | $309 |
| Hydrocortisone | 14 | $123 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Philadelphia
- Kuchikala ReddyPhiladelphia$6.5M
- Dina Halegoua de MarzioPhiladelphia$1.5M
- Gary FalkPhiladelphia$1.4M
- Kristle LynchPhiladelphia$1.3M
- Gary WuPhiladelphia$931K
- Faten AberraPhiladelphia$909K
- Ben StangerPhiladelphia$815K
- David KaplanPhiladelphia$737K
- Stacey PrennerPhiladelphia$577K
- Mark OstermanPhiladelphia$410K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.